Treatment Considerations for Specific Populations With HR+/HER2- mBC: Endocrine Sensitivity or ≥65 Years

December 12 @ 1:30 pm 2:30 pm CST

Join Dr. Hope Rugo and Dr. Adam Brufsky at this industry-sponsored program which will review treatment considerations for specific patient populations with HR+/HER2- mBC. Additional patient perspectives will be provided by a Patient Ambassador during the program, which is scheduled on Thursday, December 12th from 1:30-2:30 PM CT.


Speakers

Presenter: Hope S. Rugo, MD, FASCO
Professor of Medicine; Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Patient Ambassador
Alabama